1. Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study

   • Yingying Shen
   • Qi Liu
   • Dijiong Wu

   Original Article Open access 09 January 2023 Pages: 503 - 517

   

2. Sense of coherence or self-efficacy as predictors of health-related quality of life in sickle cell disease patients

   • Mehrnaz Ahmadi
   • Samira Beiranvand
   • Camelia Rohani

   Original Article Open access 04 November 2022 Pages: 519 - 528

3. Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine

   • Lele Zhang
   • Jin Mao
   • Jun Shi

   Original Article 21 January 2023 Pages: 529 - 539

   

4. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia

   • Masayuki Aiba
   • Akio Shigematsu
   • Takuto Miyagishima

   Original Article Open access 16 January 2023 Pages: 541 - 546

   

5. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

   • Dietger Niederwieser
   • Thomas Lang
   • Verena S. Hoffmann

   Original Article Open access 25 January 2023 Pages: 547 - 561

   

6. Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course

   • Fanny Delehaye
   • Jérémie Rouger
   • Frédéric Millot

   Original Article 12 November 2022 Pages: 563 - 570

   

7. Real-world treatments and thrombotic events in polycythemia vera patients in the USA

   • Srdan Verstovsek
   • Naveen Pemmaraju
   • Suneel Gupta

   Original Article Open access 13 January 2023 Pages: 571 - 581

   

8. FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis

   • Shihui Mao
   • Yu Qian
   • Jie Jin

   Original Article 26 January 2023 Pages: 583 - 595

   

9. Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy

   • Ying Zhu
   • Sicheng Ai
   • Haiwen Huang

   Original Article 30 January 2023 Pages: 597 - 601

   

10. Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers

    • Benedikt Frank
    • Gabriele Ihorst
    • Monika Engelhardt

    Original Article Open access 05 December 2022 Pages: 603 - 611

    

11. Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis

    • Joseph Cioccio
    • Kevin Rakszawski
    • Hiroko Shike

    Original Article 17 December 2022 Pages: 613 - 620

    

12. Autologous stem cell transplantation in multiple myeloma patients with renal impairment

    • Yingying Zhai
    • Lingzhi Yan
    • Depei Wu

    Original Article 12 January 2023 Pages: 621 - 628

    

13. Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation

    • Woochan Park
    • Ja Min Byun
    • Sung-Soo Yoon

    Original Article Open access 20 January 2023 Pages: 629 - 639

    

14. Selection bias in follow-up studies of stem cell transplantation survivors: an experience within the Maastricht Observational study of late effects after Stem cell trAnsplantation (MOSA)

    • Nicole C. van Yperen
    • Bianca Wauben
    • Harry C. Schouten

    Original Article 31 December 2022 Pages: 641 - 649

    

15. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation

    • Kimimori Kamijo
    • Yoshimitsu Shimomura
    • Eisei Kondo

    Original Article Open access 12 January 2023 Pages: 651 - 661

    

16. Can we lower the platelet threshold of ≥ 50 × 10⁹/L for performing a lumbar puncture safely in patients with hematological malignancies?

    • Aryanna Jordan
    • Akriti G. Jain
    • Michael Jaglal

    Original Article 19 December 2022 Pages: 663 - 668

17. Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia

    • Martin Stanulla
    • Denis M. Schewe
    • Britta Maecker-Kolhoff

    Letter to the Editor Open access 18 January 2023 Pages: 669 - 672

    

18. Thyrotoxicosis after unrelated cord blood transplantation for adults

    • Takaaki Konuma
    • Akira Tomonari
    • Satoshi Takahashi

    Letter to the Editor 17 December 2022 Pages: 673 - 676

19. GP1BB c.179C > T is the most frequent cause of monoallelic Bernard–Soulier syndrome in the Italian population after the Bolzano variant: a report of two new families

    • Serena Barozzi
    • Alessandro Pecci
    • Michela Faleschini

    Letter to the Editor 21 December 2022 Pages: 677 - 679

    

20. Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia

    • Alessandro Cellini
    • Federico Scarmozzino
    • Andrea Visentin

    Letter to the Editor 21 December 2022 Pages: 681 - 682

    

21. The incidence and characteristics of VTE within 100 days of CAR T-cell therapy

    • Kelly J. Gaffney
    • Mary McGann
    • Hamza Hashmi

    Letter to the Editor 19 January 2023 Pages: 683 - 685

22. Tacrolimus-induced thrombotic microangiopathy post-liver transplantation for cryptogenic acute liver failure in an infant

    • Carly Wujek
    • Rotem Fishel Ben-Kenan
    • Keith A. Sacco

    Letter to the Editor 17 December 2022 Pages: 687 - 688